Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (91-100 of 275) with videos related to

Pageof 28
Sort By:
Lung Cancer (Amsterdam, Netherlands)|July 23, 2003
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)Federico Cappuzzo, Andrea Ardizzoni, Hector Soto-Parra, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Is gemcitabine cost effective in cancer treatment?Luca Toschi, Giovanna Finocchiaro, Giovanni Luca Ceresoli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2016
cMET Exon 14 Skipping: From the Structure to the ClinicNele Van Der Steen, Elisa Giovannetti, Patrick Pauwels, et al.
Reviews on Recent Clinical Trials|April 9, 2008
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC)Giulio Metro, Giovanna Finocchiaro, Luca Toschi, et al.
Expert Opinion on Medical Diagnostics|March 16, 2013
EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?Giovanna Finocchiaro, Luca Toschi, Isabella Garassino, et al.
Frontiers in Oncology|December 16, 2022
Perioperative outcomes of robotic lobectomy for early-stage non-small cell lung cancer in elderly patientsFilippo Tommaso Gallina, Riccardo Tajè, Daniele Forcella, et al.
Journal for Immunotherapy of Cancer|May 11, 2025
Spatial transcriptomics highlights B cells as key contributors to a complete and durable response to chemo-immunotherapy in a patient with resectable NSCLCNicla Porciello, Filippo Gallina, Giuseppe Frisullo, et al.
Frontiers in Cell and Developmental Biology|December 17, 2021
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic EffectsSara Bravaccini, Giuseppe Bronte, Elisabetta Petracci, et al.
Lung Cancer (Amsterdam, Netherlands)|August 29, 2015
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) studySandro Barni, Evaristo Maiello, Massimo Di Maio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2014
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancerFederico Cappuzzo, Giovanna Finocchiaro, Francesco Grossi, et al.
Pageof 28

Showing results (91-100 of 275) with videos related to

Sort By:
Pageof 28
Lung Cancer (Amsterdam, Netherlands)|July 23, 2003
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)Federico Cappuzzo, Andrea Ardizzoni, Hector Soto-Parra, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Is gemcitabine cost effective in cancer treatment?Luca Toschi, Giovanna Finocchiaro, Giovanni Luca Ceresoli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2016
cMET Exon 14 Skipping: From the Structure to the ClinicNele Van Der Steen, Elisa Giovannetti, Patrick Pauwels, et al.
Reviews on Recent Clinical Trials|April 9, 2008
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC)Giulio Metro, Giovanna Finocchiaro, Luca Toschi, et al.
Expert Opinion on Medical Diagnostics|March 16, 2013
EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?Giovanna Finocchiaro, Luca Toschi, Isabella Garassino, et al.
Frontiers in Oncology|December 16, 2022
Perioperative outcomes of robotic lobectomy for early-stage non-small cell lung cancer in elderly patientsFilippo Tommaso Gallina, Riccardo Tajè, Daniele Forcella, et al.
Journal for Immunotherapy of Cancer|May 11, 2025
Spatial transcriptomics highlights B cells as key contributors to a complete and durable response to chemo-immunotherapy in a patient with resectable NSCLCNicla Porciello, Filippo Gallina, Giuseppe Frisullo, et al.
Frontiers in Cell and Developmental Biology|December 17, 2021
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic EffectsSara Bravaccini, Giuseppe Bronte, Elisabetta Petracci, et al.
Lung Cancer (Amsterdam, Netherlands)|August 29, 2015
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) studySandro Barni, Evaristo Maiello, Massimo Di Maio, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2014
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancerFederico Cappuzzo, Giovanna Finocchiaro, Francesco Grossi, et al.
Pageof 28